796062-33-4

Usage

Uses

Used in Pharmaceutical Industry:
3-Amino-4,4-diethoxypiperidine-1-carboxylic acid tert-butyl ester is used as an intermediate in the synthesis of various drugs. Its unique chemical structure allows for the development of new pharmaceutical compounds with potential therapeutic applications.
Used in Agricultural Industry:
3-Amino-4,4-diethoxypiperidine-1-carboxylic acid tert-butyl ester is used as a key component in the synthesis of pesticides and herbicides. Its versatility in chemical reactions enables the creation of effective agricultural chemicals to protect crops and enhance agricultural productivity.

Upstream product

• 150008-24-5 tert-butyl 4-(hydroxyimino)piperidine-1-carboxylate 
• 917-58-8 potassium ethoxide 
• 141-52-6 sodium ethanolate 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 

Downstream Products

• 1421503-44-7 4,4-diethoxy-3-{[6-[2-ethyl-5-fluoro-4-(2-trimethylsilanyl-ethoxymethoxy)phenyl]-1-(tetrahydro-pyran-2-yl)-1H-indazole-3-carboximidoyl]amino}piperidine-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOF

The present disclosure generally relates to improved synthesis of fused bicyclic Raf inhibitors of formula (I), (I-A), (I-B), (II), or (III), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof. The disclosure also relates to method o

PROCESSES FOR PREPARING AN S1P-RECEPTOR MODULATOR

This application relates to processes for preparing an S1P-receptor modulator "Compound 1", which is useful in the treatment of diseases or disorders associated with activity of S1P, including CNS disorders. The process comprises reacting "compound 2" with "compound 3" in the presence of a reducing agent.

Design and synthesis of a Pan-Janus kinase inhibitor clinical candidate (PF-06263276) suitable for inhaled and topical delivery for the treatment of inflammatory diseases of the lungs and skin

By use of a structure-based computational method for identification of structurally novel Janus kinase (JAK) inhibitors predicted to bind beyond the ATP binding site, a potent series of indazoles was identified as selective pan-JAK inhibitors with a type 1.5 binding mode. Optimization of the series for potency and increased duration of action commensurate with inhaled or topical delivery resulted in potent pan-JAK inhibitor 2 (PF-06263276), which was advanced into clinical studies.